David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

First International Summit on Interventional Pharmacoeconomics

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Mar

Today In Oncology

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Medical Societies and More Respond to HHS RFI on AI Use in Clinical Care

Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer

SABCS 2025: Top Picks From a Breast Cancer Specialist

Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer